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A b s t r a c t  
The purpose of this article on tableting of multiple Active Pharmaceutical Ingredients(APIs) in the 
single oral solid dose in the form of Fixed Dose Combinations(FDCs), that focused on therapeutic 
justification, designing, its practical approach, summarize the problem encountered and parameters 
to be considered during development.This will help budding formulation development scientists 
working on generic development as such types of formulation is current need in various disease 
conditions.Looking to the necessity of medical practitioners,ultimately generic pharmaceutical 
companies taking interest in development of such formulation with correct medical justification due 
to various health problem not only in India but also globally. FDCs are highly popular in the Indian 
pharmaceutical market and also have been seen in the last few years. Presently very few generic 
companies are working on FDCs in the form of multilayer tablets resulting into small numbers of 
formulation in the market yearly. 
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Introduction 
There are several reasons for development of combination of two 
or more drugs collectively in single dosage form in several 
diseases not only in case of emergency but also in 
commondiseaseslike parkinsonism[1], allergic rhinitis[2]etc. . The 
previous intention for development of such formulation is that when 
patient unable to take frequent dosing due to many reasons, The 
combination of different API in single dose was preferred, but these 
days if any patient suffering from one particular disease medical 
doctor primarily prescribe two or more medicine separately for the 
single illness. However, human beings thought is to get relief in 
single dose and to attain site therapeutic concentration immediately 
and maintain the same dose over 12 h or more in currently faster 
life and therefore development of FDCs gaining importance 
globally.[3] 
Very few drugs and their formulationsare available in the form 
FDCs which are therapeutically justified and are available in critical 
disease conditions. The global regulatory bodies like WHO are 
contributing for such development in untreatable diseases 
conditions for example in AIDS, cancer and pulmonary 
diseases.[4]Therefore, greater attention by various generic 
manufacturer due to FDCs gaining importance in recent years as 
Oral Solid Drug Delivery System(OSDDS) in pharmaceutical 
industries over traditional conventional or modified release single 
dose tableting due to its many advantages.[5] 
FDCs in the form of powder mixture of two or more APIÊs or 
multilayer tablets being used in the treatment of a wide range of 
conditions and are particularly useful in the management of chronic 
conditions. They areapplicable for broad range of compatible as 
well as incompatible drugs for both immediate as well as modified 
release dosage forms. It is also found that very few generic 
pharmaceutical companies having bilayer or tri-layer tablet 
compression machine and even of machinesare there is lack of 
manpower having expertise in this technology.[6] 
In India DCGI(Drug Controller General of India) published 
guidelines for FDCs in year 2010. FDCsuse to prepare products 
containing two or more active ingredients for particular 
indication/s.Several fixed-dose single tablet combinations are now 
available in domestic market for the management of various 
diseases. The most common FDCs in the form of multi-layer 
dosage form available are bilayer tablets followed by the tri-layer 
and up to four layer tablets. There are many reasons for choosing 
multi-layer tableting technology due to its different therapeutic and 
technical advantages. FDCs are not restricted to layered tablets as 
powder mixture of two or three API along with excipients 
compressed in single tablets with justified therapeutic 
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justification.[7] Currently U.S. Food and Drug Administration (FDA) 
approved TRIBENZOR™ (olmesartanmedoxomil, amlodipineand 
hydrochlorothiazide) .a new three-in-one combination product for 
the treatment of high blood pressure by Daiichi Sankyo, Inc.[8] 
Why Multilayer tableting?   
Currently about two-third of all prescriptions are dispensed as solid 
dosage forms.[9]Many combinationsare available wherein 
DUREDAS (Dual Release Drug Absorption System)technologyis 
being used which can provide immediate and modified release of 
two drugs or dual release rate of same drug in single dosage form 
by using hydrophilic and hydrophobic polymer matrices. It is 
therapeutically justified that combination of modified and immediate 
release matrix found to increase bioavailability. Compaction of 
different granules in the form of various layer in single tablets are 
called as multilayer tablets. It generally consists of parallel, clear, 
coloured, visual distinct layers two to three or more APIs or APIs 
along with functional or non-functional placebo layers, sometimes 
to avoid interaction between different incompatible layers. Many 
formulator utilised DUREDAS technological approach and its 
release rate is due to combination of diffusion or erosion or both 
through various matrices. Oral solid multiple drug delivery system 
in the form of FDCs are beneficial than the other oral formulation. 
Many of multiple API containing liquid formulations with 
preservative, alcoholetcis difficult to dispense, formulate, transport 
and to administer accurate dose.[10] 
There are many problems encountered with formulation and 
development of conventional or modified release monolithic tablets. 
Combination of immediate release and sustained release profile 
increases bioavailability and patient compliance. Three layer 
tablets are formulated for controlled release, usually consists of 
drug core layer sandwiched by external layers, which may contains 
different amount of drug to form a concentration gradient matrix or 
just act as a barrier layer in order to restrict release or to minimize 
burst effect upon in-vivo placement[11] e.g. UROXATRAL® 
(alfuzosinHCl extended-release tablets) consists of a hydrophilic 
active matrix core enclosingalfuzosin hydrochloride in a single layer 
supported by two inert and non-functional layers (one swellable 
layer and one erodible layer) whose functions are to control the 
hydration and swelling rate of the core, and thereby slow down 
dissolution of the drug.[12] When the tablet comes into contact with 
gastric juices, it increases considerably in volume and thus remains 
in the stomach for a longer time. There are many reasons for 
choosing multi-layer tableting technology due to different 
therapeutic and technical advantages. 
Therapeutic advantages 
Better execution of release profile 
Layering on the tablet revealed betterexecution on release profile 
and it is one of the most important possible alternatives to 
conventional matrix tablets to avoid the initial burst release and to 
achieve zero-order release profile, which maintain availability of 
drug over 12 h or more.Eg.venlafaxine hydrochloride.[13] 
Decrease burst effect and fast initial release rate 
Upon placement of controlled release formulation in release 
medium or in dissolution medium, there is an immediate release of 
an initial large bolus of drug, before the release rate reaches a 
stable profile (stable matrix formation). This phenomenon is 
typically referred to as 'burst release' which is controlled using 
multilayer tableting.eg. terazosinHCl.[14] 
Multiple release profiles 
Two or more layers in tablets are able to provide multiple release 
kinetics of same or different drugs of same or different 
physicochemical properties and it is possible to formulate each 
monolith in order to parcel out the delivery of drug dose by means 
of different release control mechanisms.Eg.Naproxen, loratadine 
and pseudoephedrine. [15] 
Synergistic effects 
 It is well known thatpresence of one drug enhances the effects of 
the second and formulation of two or more drugs together in single 
tablets offer therapeutic effect of these drugs is greater than the 
sum of the individual effects. [16] 
Reduction in dosing frequency 
It is possible to formulate one layer in the form ofimmediate 
releasedisintegrating monolith that deliver the initial quick release 
required to achieve peak plasma concentration and then sustaining 
the same drug over the period of time more than 12 h so the 
multiple intake dosing frequency minimize and thus get 
programmable drug delivery system of same or different active in 
single dose and thus reduction in dosing frequency.[13] 
Delayed Release  
Application of erodible monolithfor immediate and delayed 
releasepattern is possible, which deliver the second instalment of 
drugs in the latter part of GIT. E.g. naproxen and esomeprazole 
magnesium. [17] 
Controlled Release 
Swelling monolith carry out by both swelling as well as eroding 
mechanism in which drug was continuously released throughout 
the GIT. E.g. Trimetazidinedihydrochloride. [18] 
Patient compliance   
Improved patient compliance by reducing tablet intake, "Layers" in 
tablets represented by two clearly different colours and produces a 
product that looked more attractive than a standard white "pill". 
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Some double-layer products are coated and appearing to be 
comprised of one uniform substance. This allows a decrease in the 
dosing frequency and a reduction in peak plasma concentrations, 
thereby improving patient compliance.  
Technical advantages 
Dual release profile 
Multilayered tablets provide dual release repeat-action, in which 
one layer of tablet or outer compression coated layer provides the 
initial dose in the form of rapidly disintegrating matrix in the 
stomach and inner layer tablet is formulated with components that 
are insoluble in gastric media but release in the intestinal 
environment. [19] 
Release restriction 
 Multilayer tablet give restriction to release surface of swellable 
matrix by barrier layers (two or three layer) and possible to create 
differential layer dissolution profile. [20] 
Flexibility 
 Maximum suppleness in drug release patterns, ease of 
manufacturing, increase in safety boundary of high potency drug 
and reduction in health care cost etc. 
Manufacturing 
 Two or more drugs are compressed in to single tablets by using 
modified multilayer tablet press. It is possible to avoid the 
incompatibility in between active-active, excipient-excipient and 
active-excipients by mean of physical separation in the form of 
multilayer and also Millard reactions occurring during tablet 
compression. [21] 
Multitalented 
It has higher drug loading capacity and ability to release multiple 
APIs with broad range of release profiles and ability to separate 
incompatible APIÊs. Cost saving can be achieved by reducing 
manufacturing activities, overall unique and cost effective dosage 
form. 
Regulatory advantages 
 Expansion of patent life by preparing pharmaceutical alternative of 
same or different drugs or new therapeutically justified combination 
of drug product and possibility of patenting and registering the 
product in various markets worldwide.   
Disadvantages 
Problems during In-process Quality Control(IPQC) 
 In-processproblems during bilayer compression such as layer-
separation(delamination) occurs; sometimes not immediately but 
may be after compaction i.e. during storage, packaging, shipping. 
Problem such asinsufficient hardness, inaccurate individual layer 
weight control, cross-contamination between the layers, insufficient 
binding between layers, reduction in practical yield of final 
compressed tablets, clear visual separation between the two layers 
are commonly observed. [5] 
Analytical Development and Pharmacopoeial 
Monograph 
It has been observed that very few FDCs monographs are 
available in various pharmacopoeias like USP, JP, IP, BP etc. 
Analytical developments of many FDCs are not included in 
pharmacopoeias.Preparations of finished product specification 
takelong time for development of dissolution testing, assay, content 
uniformity and characterization of impurities. Moverover, issue 
related to development of cleaning validation, detection of residue 
after cleaning validation, determination of LOD, selection of primary 
packaging material for different types of physicochemical 
properties of individual active pharmaceutical ingredients in 
finished products are to be addressed.   
Regulatory  
It is true that development of FDCs should always be based on 
believable therapeutic and medical justification which is clinically 
relevant. Hence various pharmaceutical companies are demanding 
that individual compounds of same formulation available in market 
are safe and effective since long time and therefore FDCs of same 
are also safe but DCGI had restriction for development of FDCs. 
Unfortunately, many FDCs have been introduced in Indian market 
are usually irrational and therefore, many irrational combinations 
are banned by DCGI and guidelines wereissued for getting 
marketing approval of FDCs. These guidelines concern to 
manufacture/ import and marketing approvals. [22] 
Machine setup 
Set up of bilayer or trilayer tablets is time consuming, take long 
time to initial setup, speed, requirement of skilled person and many 
times problem arise during tableting as compared to single layer 
conventional tablet press in machine setup, cost and production 
output.  
Ideal properties of multilayer tablets [23] 
1. Layer should not fuse into non-disintegrating matrix, should have 
clear, parallel, visual separation in final compressed tablets. 
2. If it consists of disintegrating matrix, it should be disintegrated 
within GIT, modified release part should not be affected dissolution 
profile of IR part and slow and gradual erosion of second layer for 
slow release of drug. 
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3. Drug should not be affected by compaction of each layer and 
physically stable; and withstand the mechanical shock. 
4. Separation of layers should not occur during various stages such 
as compression, coating, packing, shipping and storage. 
Objective of preparing multilayer tablets 
1. To treat critical disease condition when single active unable to 
produce complete therapeutic action and to maintain over a period 
12 h or more. E.g. telmisartan/amlodipine tablet[24, 25] 
2. To use combination having proven advantages over single 
compounds administered separately for therapeutic effect. [26, 27] 
3. To combine different drugs for synergistic therapeutic effect or 
different drugs in order to achieve a specific release profile. E.g. 
efavirenz, emtricitabine, and tenofovirdisoproxilfumigate in 
multilayer tablet for the treatment anti HIV-1 infection. [28] 
4. To overcome the limitations in case of a single drug which is 
unable to treat or avoid adverse drug effect, if any.  
5. To establish a brand identity, as they are clearly different from 
other products from generic competitors and also from patient 
identity over routine white pills and when patient is unable to take 
frequent dosing of same drug.    
6. To get dual release profile so as to reduce tablets intake and 
thereby increasing patient compliance. 
7. To combine compatible or incompatible drugs with different 
release characteristic in same dosage form and enhancing the 
stability of dosage form as compared to its conventional monolith 
counterpart. 
Steps involved in preparation of bilayer tablets  
Parameters to be considered during Multilayer tableting [5, 29] 
Following parameters primarily be considered during multilayer 
tableting.ItÊs totally depending upon handling and experience of 
such multi-dosing tablet press.    
Dwell time 
It is the contact between punch head and compression roller. If 
shorter the first layer-dwell time, which results into pours, aeration, 
capping and hardness problems.It may be removed the mistakes 
by reducing the turret-rotation speed or by extending the dwell 
time. 
Risk of separation and capping 
It is necessary to avoid risk of separation and capping, by forming 
correct bonding which can be attained by the first layer formation at 
low compression force. Therefore this first layer can still interact 
with the second layer during final compression of the tablet. 
Cohesiveness 
When the first layer is compressed at a very high compression 
force,bonding between layers is severely controlled. Various 
bilayer formulations necessitate a first layer compression force 
NMT 3 Kpor 30 N to maintain the ability of first layer to bond with 
the second layer. Above 50 Nforces, this ability may be gone 
astray and thus bonding between layers may be insufficient, 
resulting in little hardness which leading to layer separation. Thus 
at elevatedmanufacturing speed, the jeopardy of separation and 
capping increases which can be minimised by adjusting adequate 
dwell time at all compression stages. 
Tamping force 
Tamping force applied on the first layer of bilayer tablet to 
circumvent capping and separation of the two individual layers. If 
dwell time is increased at pre-compression of both first and second 
layer, it provides sufficient hardness and also low pre-compression 
forces,which is required to secure interlayer bonding. 
Cross-contamination 
 Multilayer tablet machines are equipped with suction nozzles or 
dust extractor to remove fine powder or granules to eliminate 
cross-contamination between the two layers and getting a clear 
visual separation between layers. It is very important to remove 
any powder residue from the die plate and for this purpose 
dedicated scraper plate are located before and after each die fill, to 
remove residual powder dust to the outside of the die table, where 
the high efficiency suction nozzles are located.  
Deaeration 
 If dwell time increases, it increases the deaeration of the powder 
and the re-arrangement of the granules in the die. So, these two 
factors increase the hardness of the tablets significantly and avert 
potential capping problems. [30] 
Final compression force 
 This force is applied on the final bilayer tablet is always more than 
the compression force on first layer,which results in suitable 
bonding of both the layers. 
Re-circulation 
 Powder is always re-circulated over the turret whereas, other 
granules having powder outlet, in order to reduce mixing.Some 
modified release compression machine not recommended due to 
limitation of recirculation of powder as it can create more dust and 
risk of contamination  
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Formation of multilayer tablets 
 
 
Fig.1. Steps involved in preparation of bilayer tablets 
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Table 1. Technology used for different layer tablets 
Company Name of Technology Approach 
Skye 
pharma[31] 
Geomatrix Technology One or two impermeable polymeric coating applied on one 
or both bases of the core tablet. 
Accu-Break 
pharmaceutical
s, Inc[32] 
Accu-Break Technology: Accu-B &Accu-T 
bilayer or tri-layer tablet technology 
Suitable for FDCs combination, easily divided, and ability to 
separate IR from CR and to take appropriate half tablets 
and the free layer drugdose not affect drug release. 
Alza 
Corporation[33] 
OROS push pull technology, Bilayer or 
trilayer core 
Consists of one push layer and 1 or more drug layer, 
osmotic agent & water swellable polymer 
Flamel 
Technologies[3
4] 
FlamelMicropump technology Permits DR and ER drug delivery system  
Elan Drug 
Technologies[3
5] 
DUREDAS Dual Release Drug Absorption 
System  
Immediate and sustained release rates of drug 
Table 2. Different two drugs in individual layer of bilayer tablet 
 
 
Table 3: Commercially available bilayer tablets 
Product Name Chemical Name Developer Therapeutic  
Alprax Plus [43] 
 
Sertraline, Alprazolam Torrent Pharmaceutcals Ltd. Anti-depressant 
Glycomet®-GP2Forte [44] Metformin hydrochloride, 
Glimepiride 
USV Limited Anti-diabetic 
Drug 1 Drug 2 Objective Purpose Ref.
Paracetamol 
 
Diclofenac                     
sodium 
Immediate release of 
paracetamol and tailored 
release of diclofenac sodium  
Reduce dose frequency and 
decrease incidence of GI side 
effects 
[36]
Metformin 
hydrochloride 
Pioglitazone 
 
Metformin HCl in extended 
release matrix form and 
Pioglitazone HCl in immediate 
release form for the treatment 
of diabetes mellitus 
Decrease frequency of 
administration and improve 
patient compliance 
[37]
Tramadol 
 
Acetaminophen Prolonged release of  
tramadol and 
acetaminophenup to 12 h 
Prolonged release up to 12 h and 
improve patient compliance 
[38]
Salbutamol 
 
Theophylline Bilayer sustained release 
tablet of salbutamol and 
theophylline 
Increase patient compliance and 
prolong      bronchodilation 
[39]
Metoprolol 
succinate 
 
Amlodipinebesylate 
 
Metoprolol succinate as 
sustained release and 
amlodipine besilate as 
immediate release 
Lower doses of drug to reduce 
patientblood pressure, minimize 
dose dependent side effects and 
adverse reactions 
[40]
Atorvastatin 
calcium 
Nicotinic acid atorvastatin calcium as an 
immediate release layer and 
nicotinic acid as an extended 
release layer 
Develop potential dosage form [41]
Metoclopramide 
hydrochloride 
Ibuprofen Immediate release of 
metoclopramide hydrochloride 
andsustained release 
ibuprofen for the effective 
treatment of migraine 
Effective treatment of migraine 
and avoid    chemical 
incompatibility between drugs 
[42]
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Weight variation 
Weight variation occurs some time due to non-uniform flow of 
granules, incomplete die filling and lower punch jamming due to 
excessive fines in final blend and thus these parameters should be 
controlled carefully during tableting.  
First layer weight layer measurement 
 when producing multilayer tablets, this stage is challenging for 
different reasons because sampling of first layer for weight check 
at the start and in-between compression cycle is difficult.For this 
reason, first weight layer is compressed at high hardness to make 
sampling and easy separation and weighing is possible because 
first layer hardness is generally low and difficult to handle.Once the 
target weight of first layer achieves, reduce pressure as much as 
20 to 30 N. Many modified tablet press has push button which 
automatically separate layered tablet due to pressure difference.  
Weight adjustment 
 First layer pressure is useful for weight adjustment of second 
layer.Manyformulators use such technique to achieve desired 
weight instead of using weight adjustment knob that totally 
depends on handling experience of such double rotary press.   
Layer weight ratio 
 Generallylayerweight ratios 50:50, 60:40 and 25:75 are used for 
formulation of such tablets, provided that granules are having good 
binding property.  
To get high yield 
 This isone of main consideration during the multilayer 
compression. It is different from the single layer compression 
machine in which manufacturing loss limits 2 to 3 % in most cases, 
whereas, in multilayer tableting manufacturing losses can be very 
high such limits may increase up to 5 to 15 % . It is because of loss 
of granules or blend during the compression, which is mainly due 
to dust suction nozzle for controlling dusting or excessive fines of 
granules on turret. It avoid cross contamination with other granules 
present on turret.  Suction nozzles aresituated on both sides of 
each feed frame. If the flow of granules not properly controlled 
during compression, excessive sucking of granules occurs and this 
loss may increase than standard limits. Chances of loss of 
granules from the entrance of feed frame are also possible if the 
feed frame is not properly adjusted.Incoming granules flow from 
turret to feed frame may sucked by nozzle before reaching in feed 
frame. The second parameters is out coming granules from first 
feed frame, which is again collected and reused but due to 
improper fitting of feed frame loss of granules is increased and thus 
affect the final yield. 
Hardness and Thickness 
Thisparameters need to be tightly controlled during final 
compression because it directly affect the release of active. Many 
times due to high hardness disintegrating matrix may take time 
more than limits. 
Segregation 
Sometimes segregation occurs in out coming granules in most 
machines and therefore it is better to blend granules before putting 
into hopper for reuse to minimize the content uniformity in finished 
products. 
Multilayer tablet presses  
Many companies having leadership in Pharma machinery supply 
machines from single layer to two to three layered tableting for lab 
scale such as Cadmach, Karnavati, Elizabeth-Hata, KG pharma, 
Fette, GEA Process Engineering,Korsch etc. It has D or B or both 
types of tooling with additional facility for manufacturing in various 
sizes and shape with maximum output with advanced facilities.   
Examples of few Technologies with familiar marketed 
FDCs 
Many patented technologies available for development of FDCs 
formulation and their marketed FDCs as shown in table 1. 
Conclusion 
Multilayer tablet can be considered as a promising delivery system 
for oral delivery of drugs useful in diseases and/or disorders such 
as hypertensive, HIV, tuberculosis, diabetic, bacterial infection etc. 
The multilayer tablet is used to provide sequential release of more 
than twoincompatible drugs in combination and also for sustained 
release. In case of bilayer tablet, generally it was found that one 
layer is immediate release as initial dose and second layer is 
maintenance dose. Several pharmaceutical industries are presently 
developing multilayer tablets for a variety of reasons like patent 
extension and to reduce capital investment. 
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